Subventions et des contributions :

Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019).

Salmonella infections represent a significant public health concern and disease burden. Significant sources ofx000D
infection are typically contaminated meat and poultry, eggs, and fresh produce. As such, the control ofx000D
Salmonella infections in poultry products is one means to reduce human infections. While advances have beenx000D
made in reducing the frequency of Salmonella contamination in processed poultry, there is mounting pressurex000D
on commercial producers to prevent and/or eliminate these pathogens in pre-harvest production facilities.x000D
NovoBind Livestock Therapeutics Inc. proposes to develop a novel antibody-based therapeutic strategy thatx000D
could be provided to commercial growers to prevent and/or eliminate Salmonella pathogens in pre-harvestx000D
poultry production facilities. Currently, novel Salmonella-specific antibodies have been generated and arex000D
being tested for their efficacy using in vitro and in vivo methods. The work proposed here capitalizes on thex000D
expertise of Dr. Eric Accili in the fields of protein biochemistry and gastrointestinal (GI) tract biology. Thisx000D
project proposes to develop antibody formulations appropriate for application in the GI tract. The developmentx000D
of a Salmonella-selective antibody that is highly effective in the GI tract would benefit Canadian and Worldx000D
populations by reducing human infection and illness, loss of life and costs of treatment. The revenue generatedx000D
by NovoBind in delivering this product would also be an economic boost to Canada.